查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2000707

疫苗佐劑市場：按給藥途徑、製劑、疫苗類型和最終用戶分類的全球市場預測 – 2026–2032 年

Vaccine Adjuvants Market by Delivery Route, Formulation, Vaccine Category, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，疫苗佐劑市值將達到 9.4788 億美元，到 2026 年將成長至 10.1993 億美元，到 2032 年將達到 16.6517 億美元，年複合成長率為 8.38%。

主要市場統計數據
基準年 2025 9.4788億美元
預計年份：2026年 1,019,930,000 美元
預測年份 2032 1,665,170,000 美元
複合年成長率 (%) 8.38%

這本入門書籍全面說明了各種疫苗技術和佐劑在臨床環境中的科學背景、監管框架和戰略重要性。

疫苗佐劑已從單純的添加劑發展成為對疫苗效力、免疫反應持久性和分發模式具有重大影響的策略要素。近年來，製劑科學、給藥途徑創新和監管要求的相互作用，使得佐劑的選擇從下游製劑決策提升為早期設計階段的關鍵參數。隨著相關人員應對日益複雜的生物學挑戰，從新一代mRNA平台到複雜的重組構建體，佐劑既是科學優勢，也是商業性差異化的關鍵因素。

科學突破、監管現代化和商業性整合的整合如何從根本上改變疫苗佐劑的研發和應用動態。

疫苗佐劑領域正經歷一系列變革，其驅動力包括技術進步、監管現代化以及相關人員期望的轉變。從科學角度來看，人們對核酸疫苗的興趣激增，促使人們研究能夠增強抗原呈現和細胞免疫的佐劑，從而推動了對新型脂質和顆粒載體的研發投入。同時，鼻腔和口服給藥途徑的創新也迫使製劑研發人員重新思考穩定性和黏膜免疫抗原性，而不只依賴全身注射的特性。

2025 年美國關稅措施對輔助供應鏈中採購、製造和策略採購的重組的營運、供應鏈和監管影響。

美國2025年生效的關稅政策對疫苗佐劑生態系統內的供應鏈、籌資策略和跨境生產決策產生了連鎖反應。依賴進口原料、特殊脂質和關鍵顆粒添加劑的公司立即面臨進口後原物料成本和採購前置作業時間的壓力。因此，採購團隊加快了供應商資格合格流程，探索了近岸替代方案，並增加了庫存緩衝，以確保臨床試驗進度並履行商業性承諾。

高解析度細分分析，將遞送途徑、配方類型、最終用戶環境和疫苗類別與技術和商業性決策標準相匹配。

基於細分市場的觀點揭示了指導佐劑領域開發、商業化和應用方案的實用差異化因素。臨床目標因給藥途徑的不同而顯著差異。肌注仍然是全身免疫和高效臨床路徑的既定標準。鼻內給藥著重於黏膜免疫，並可能改變製劑穩定性要求。口服給藥強調可擴展性和患者耐受性，但需要確保其抗酸酶穩定性。皮下給藥涉及特定的劑量和耐受性限制，這些限制會影響輔料的選擇。

區域戰略觀點：揭示美洲、歐洲、中東和非洲以及亞太地區如何對佐劑策略施加不同的政策、製造和採用壓力。

區域趨勢對佐劑研究重點、生產策略和市場准入有顯著影響。在美洲，私部門的創新中心和活躍的創業投資持續加速轉化研究和早期臨床計畫的推進，而先進的生物製造能力則支持已達到監管里程碑的計畫快速擴大規模。此外，該地區的政策框架鼓勵官民合作關係，並為國內生產提供獎勵，從而影響製造商和開發商的投資決策。

透過獨特的技術、服務產品和在佐劑生態系統中整合的製造能力，使公司脫穎而出的策略行動和夥伴關係模式。

疫苗佐劑生態系統中的主要企業正採用多種差異化策略組合來確保競爭優勢。一些企業優先發展專有製劑平台和專利化學技術，大力投資於作用機制研究和基於生物標記的差異化，以建立永續的智慧財產權競爭優勢。另一些企業則採用服務主導模式，為追求速度和監管認可的疫苗研發企業提供製劑開發、分析等效性評估和契約製造服務。

優先考慮經營團隊，以增強供應韌性，簡化監管合規流程，並加速輔助創新在整個價值鏈中的臨床應用。

為了將洞見轉化為有效行動，產業領導者應採取一系列優先措施，以增強韌性並加速臨床應用。首先，實現關鍵原料來源多元化，並對高風險添加劑和脂質採取多源採購策略，以降低關稅和地緣政治衝擊的影響。同時，投資於區域製造夥伴關係和技術轉讓，以建立冗餘機制，並維持快速推進臨床應用。

一種透明且可重複的調查方法，它整合了與專家的初步訪談、文獻整合、專利和監管分析以及可靠的交叉檢驗技術。

本報告提出的結論和建議是基於嚴謹的調查方法，該方法結合了第一手資料和第二手資料，並透過與專家的對話檢驗。第一手資料研究包括與臨床研究人員、藥物科學家、監管專家和生產管理人員進行結構化訪談和共識研討會，以確定實際應用中的限制和策略重點。第二手資料研究則利用同儕審查文獻、臨床試驗註冊資訊、專利資料庫和監管指導文件，梳理科學進度和監管先例。

策略性地整合關鍵見解，突出可操作的優先事項，以協調佐劑開發中的科學創新、生產韌性和監管合作。

總之，疫苗佐劑如今在疫苗研發中扮演核心策略角色，影響著免疫抗原性、給藥物流和商業性差異化。製劑設計和給藥途徑的技術進步，加上不斷變化的監管預期和供應鏈的脆弱性，既為研發人員、生產商和醫療保健系統帶來了機遇，也帶來了營運上的挑戰。那些能夠將科學嚴謹性、生產柔軟性和積極的監管合作相結合的相關人員，將更有能力將佐劑創新轉化為安全、有效且廣泛可用的疫苗。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依給藥途徑分類的疫苗佐劑市場

  • 肌肉內部
  • 鼻腔
  • 口服
  • 皮下

第9章：按製劑分類的疫苗佐劑市場

  • 乳液
  • ISCOM
  • 脂質體
  • 細顆粒物
  • 皂素複合物

第10章：以疫苗類型分類的疫苗佐劑市場

  • 細菌疫苗
  • DNA疫苗
  • 藥效疫苗
  • 重組疫苗
  • 病毒疫苗

第11章：疫苗佐劑市場：依最終用戶分類

  • 診所
    • 門診部
    • 專科診所
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究機構
    • 政府附屬組織
    • 私人研究機構

第12章：疫苗佐劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：疫苗佐劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：疫苗佐劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國疫苗佐劑市場

第16章：中國疫苗佐劑市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agenus, Inc.
  • Aphios Corporation
  • Bioveta, AS
  • Croda International PLC
  • CSL Limited
  • Dynavax Technologies Corporation
  • GlaxoSmithKline PLC
  • Hayashibara Co. Ltd.
  • InvivoGen
  • Merck KGaA
  • MVP Laboratories, Inc.
  • Novavax, Inc.
  • OZ Biosciences
  • Pacific GeneTech Limited
  • Seppic SA
  • SHIONOGI & Co., Ltd.
  • SPI Pharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Vaxine Pty Ltd.
  • Zoetis Services LLC
Product Code: MRR-02026C4C8667

The Vaccine Adjuvants Market was valued at USD 947.88 million in 2025 and is projected to grow to USD 1,019.93 million in 2026, with a CAGR of 8.38%, reaching USD 1,665.17 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 947.88 million
Estimated Year [2026] USD 1,019.93 million
Forecast Year [2032] USD 1,665.17 million
CAGR (%) 8.38%

A comprehensive primer that contextualizes the science, regulatory boundaries, and strategic importance of adjuvants across diverse vaccine technologies and clinical settings

Vaccine adjuvants have evolved from ancillary additives into strategic enablers that materially influence vaccine efficacy, durability of immune response, and distribution models. In recent years, the interplay between formulation science, delivery route innovation, and regulatory expectations has elevated adjuvant selection from a downstream formulation decision to a critical early-stage design parameter. As stakeholders navigate increasingly complex biological challenges-from next-generation mRNA platforms to complex recombinant constructs-adjuvants are both a scientific lever and a commercial differentiator.

This introductory analysis synthesizes core scientific principles, key development inflection points, and regulatory touchstones that shape adjuvant advancement. It highlights how delivery route choices such as intramuscular, intranasal, oral, and subcutaneous administration influence formulation constraints and clinical endpoints. Moreover, it underscores how formulation classes including emulsions, immune-stimulating complexes, liposomes, particulate systems, and saponin complexes present distinct manufacturability and stability profiles that directly affect downstream decisions.

Finally, this primer situates end user considerations across clinics, hospitals, and research institutes, and examines how vaccine categories spanning bacterial, DNA, mRNA, recombinant, and viral platforms intersect with adjuvant strategy. By grounding the discussion in these foundational elements, the reader obtains a coherent frame to assess subsequent strategic and operational implications.

How converging scientific breakthroughs, regulatory modernization, and commercial integration are fundamentally reshaping vaccine adjuvant development and adoption dynamics

The landscape for vaccine adjuvants is undergoing a series of transformative shifts driven by technological advances, regulatory modernization, and changing stakeholder expectations. At a scientific level, the surge of interest in nucleic acid vaccines has necessitated adjuvant research that augments both antigen presentation and cellular immunity, prompting renewed investment into novel lipid and particulate carriers. Concurrently, innovations in intranasal and oral delivery routes are forcing formulators to rethink stability and mucosal immunogenicity rather than relying solely on systemic injection profiles.

On the regulatory front, agencies are clarifying pathways for adjuvant-containing constructs while simultaneously demanding robust justification for safety and mechanism of action. This regulatory tightening encourages earlier and deeper dialogue between developers and regulators, and increasingly rewards structured preclinical immunoprofiling and translational biomarkers. Commercially, the advent of platform technologies has shifted value creation toward integrated solutions where adjuvant expertise is bundled with antigen design and delivery systems, motivating strategic alliances between specialty adjuvant developers, vaccine innovators, and contract manufacturers.

Taken together, these shifts accelerate the consolidation of technical capabilities, raise the bar for evidentiary standards, and create differentiated pathways to clinical adoption. As a result, organizations that align scientific investment with regulatory foresight and supply chain resilience will gain decisive advantages in a market defined by both rapid innovation and heightened scrutiny.

Operational, supply chain, and regulatory ramifications of the 2025 United States tariff measures reshaping procurement, manufacturing, and strategic sourcing in the adjuvant supply chain

The introduction of United States tariffs in 2025 has produced a ripple effect across supply chains, procurement strategies, and cross-border manufacturing decisions within the vaccine adjuvant ecosystem. Companies dependent on imported raw materials, specialized lipids, and key particulate excipients experienced immediate pressure on landed input costs and procurement lead times. In turn, procurement teams accelerated supplier qualification processes, sought near-shore alternatives, and increased inventory buffers to preserve clinical timelines and commercial commitments.

Beyond direct cost effects, tariffs reinforced strategic reassessments about geographic concentration of production. Developers and contract manufacturers began evaluating the trade-offs between onshore manufacturing investments and the economics of globalized supply. Regulatory considerations compounded these operational shifts, since any change in source materials or manufacturing sites often triggers comparability studies and supplementary regulatory filings-activities that consume both time and scientific resources.

Importantly, the tariffs also highlighted the structural interdependencies between raw material sourcing, intellectual property overlays, and export controls for advanced adjuvant platforms. Stakeholders responded by diversifying supplier networks, investing in multi-sourcing strategies for critical excipients, and accelerating technology transfers where feasible. Ultimately, the cumulative impact extended beyond immediate cost adjustments, compelling a strategic reorientation toward supply chain resilience and manufacturing flexibility that will influence program design and partnership choices over the medium term.

High-resolution segmentation analysis that aligns delivery routes, formulation types, end-user environments, and vaccine categories with technical and commercial decision criteria

A segmentation-driven view surfaces actionable differentiators that inform development, commercialization, and deployment choices across the adjuvant landscape. When considering delivery route, the clinical objectives vary materially: intramuscular administration remains the established standard for systemic immunity and streamlined clinical pathways; intranasal approaches prioritize mucosal immunity and can alter formulation stability demands; oral delivery emphasizes scalability and patient acceptability but requires acid- and enzyme-stability engineering; subcutaneous delivery presents distinct volume and tolerability constraints that influence excipient selection.

Formulation segmentation reveals trade-offs among technology classes. Emulsions offer proven potency with recognizable manufacturing footprints, while immune-stimulating complexes (ISCOMs) provide targeted antigen presentation advantages but carry more complex assembly and characterization requirements. Liposomes deliver versatility for both small and large antigens and dovetail with nucleic acid modalities, whereas particulate systems enable depot effects and sustained release. Saponin complexes deliver robust adjuvant activity with specific safety and sourcing considerations that must be proactively managed.

End user segmentation influences adoption pathways. Clinics, including outpatient and specialty settings, demand low-complexity administration and strong cold-chain resilience. Hospitals, both private and public, prioritize scalable stock management and integration with immunization schedules. Research institutes, spanning government bodies and private laboratories, drive early innovation and validation work that feeds commercialization pipelines. Finally, vaccine category segmentation-covering bacterial, DNA, mRNA, recombinant, and viral vaccines-dictates differential immunological endpoints and regulatory data expectations, requiring tailored adjuvant strategies that align scientific mechanism with clinical objectives.

A regional strategic lens revealing how the Americas, Europe Middle East & Africa, and Asia-Pacific exert distinct policy, manufacturing, and adoption pressures on adjuvant strategies

Regional dynamics exert a powerful influence over research prioritization, manufacturing strategy, and market access for adjuvants. In the Americas, private sector innovation hubs and strong venture capital activity continue to accelerate translational research and early clinical programs, while advanced biomanufacturing capacity supports rapid scale-up for programs that clear regulatory milestones. Policy frameworks in this region also encourage public-private partnerships and incentives for domestic production, which shape investment calculus for manufacturers and developers.

In Europe, Middle East & Africa, regulatory harmonization efforts and collaborative procurement mechanisms drive different adoption timelines and evidence requirements. Europe's dense regulatory expertise and established contract manufacturing ecosystems support complex formulation development, whereas countries across the Middle East and Africa emphasize readiness, supply security, and local manufacturing partnerships to improve access. These heterogeneous priorities require tailored engagement strategies by developers that respect regional regulatory expectations and procurement practices.

Asia-Pacific displays pronounced diversity between advanced biopharma markets and rapidly developing ecosystems. Regional supply chain strengths, particularly in specialized excipient production and large-scale fill-finish operations, create opportunities for vertical integration and cost-efficient manufacturing. Simultaneously, growing domestic R&D capabilities and strategic government investments in biotech infrastructure are creating new centers of excellence that accelerate adoption for novel adjuvant technologies. Collectively, these regional patterns inform strategic decisions about partnership models, localization, and regulatory engagement.

Strategic corporate behaviors and partnership models that differentiate firms through proprietary science, service offerings, and integrated manufacturing capabilities within the adjuvant ecosystem

Leading organizations in the vaccine adjuvant ecosystem are deploying a mix of differentiated strategies to secure competitive advantage. Some firms prioritize proprietary formulation platforms and patent-protected chemistries to create durable intellectual property moats, investing heavily in mechanism-of-action studies and biomarker-driven differentiation. Others adopt a services-led model, offering formulation development, analytical comparability, and contract manufacturing capabilities that cater to vaccine developers seeking speed and regulatory confidence.

Strategic partnerships are another central theme: alliances between specialized adjuvant developers and large vaccine manufacturers accelerate clinical translation and broaden access to late-stage development expertise. Contract development and manufacturing organizations have also expanded capabilities to support complex adjuvant formulations, including lipid systems and particulate assemblies, which reduces technical risk for sponsors. Additionally, technology transfers and licensing agreements play an outsized role in enabling geographic manufacturing scale-up while preserving core proprietary elements.

Finally, several players are integrating digital and data-driven approaches to improve formulation screening, stability modeling, and supply chain visibility. By combining high-throughput experimental platforms with advanced analytics, companies are shortening iteration cycles and improving predictability in development outcomes. Together, these corporate behaviors illustrate a competitive landscape that values both deep technical differentiation and pragmatic operational excellence.

Priority actions for executives to bolster supply resilience, streamline regulatory alignment, and accelerate clinical translation of adjuvant innovations across the value chain

To translate insight into effective action, industry leaders should adopt a prioritized set of measures that strengthen resilience and accelerate clinical translation. First, diversify critical raw material sources and pursue multi-sourcing strategies for high-risk excipients and lipids to reduce exposure to tariff and geopolitical shocks. Simultaneously, invest in regional manufacturing partnerships and technology transfers that preserve speed to clinic while building redundancy.

Second, align early-stage development with regulatory expectations through proactive engagement. Incorporate mechanism-of-action studies, translational biomarkers, and robust comparability plans into development programs to anticipate data requirements and shorten review cycles. Third, optimize formulation strategies by matching adjuvant class to delivery route and vaccine category: select systems that balance immunogenic potency with manufacturability and stability under realistic distribution scenarios.

Fourth, pursue collaborative models that blend proprietary innovation with service capacity-partner with contract developers and academic centers to de-risk scale-up and leverage external manufacturing expertise. Finally, embed data-centric capabilities across R&D and supply chain functions to improve predictability, from in silico screening to shelf-life forecasting. Taken together, these recommended actions create a pragmatic roadmap for organizations seeking to convert scientific promise into reliable clinical and commercial outcomes.

A transparent, reproducible research methodology integrating expert primary interviews, literature synthesis, patent and regulatory analysis, and robust cross-validation practices

The conclusions and recommendations presented in this report rest upon a rigorous methodology combining primary and secondary evidence streams validated through expert engagement. Primary research included structured interviews and consensus workshops with clinical investigators, formulation scientists, regulatory affairs specialists, and manufacturing leaders to surface real-world constraints and strategic priorities. Secondary research relied on peer-reviewed literature, clinical trial registries, patent databases, and regulatory guidance documents to map scientific trajectories and regulatory precedents.

Analytical techniques encompassed qualitative thematic analysis, cross-validation of technical assumptions, and synthesis of manufacturing and supply chain risk indicators. Where comparability or generalizability was required, triangulation across independent sources ensured robustness of interpretation. Quality assurance steps included iterative review cycles with subject-matter experts, reconciliation of conflicting evidence, and sensitivity checks on key technical inferences.

The methodology intentionally emphasized transparency and reproducibility: all sources and analytical decisions are cataloged in the methodological annex, and key uncertainties are explicitly called out to inform risk-aware decision-making. This approach enabled the development of actionable insights that reflect both the current scientific state and operational realities facing adjuvant developers and their partners.

Strategic synthesis of core findings emphasizing actionable priorities to align scientific innovation, manufacturing resilience, and regulatory engagement in adjuvant development

In synthesis, vaccine adjuvants now occupy a central strategic role in vaccine development, influencing immunogenicity, delivery logistics, and commercial differentiation. Technological advances in formulation design and delivery routes, coupled with evolving regulatory expectations and supply chain sensitivities, create both opportunities and operational complexities for developers, manufacturers, and health systems. Stakeholders that integrate scientific rigor, manufacturing flexibility, and proactive regulatory engagement will be best positioned to translate adjuvant innovations into safe, effective, and widely adoptable vaccines.

Near-term priorities include securing resilient supply chains, aligning early development programs with regulatory evidence expectations, and selecting formulation-delivery combinations that reflect end-user realities across clinics, hospitals, and research institutions. At the same time, regional dynamics and tariff-influenced sourcing strategies necessitate careful assessment of manufacturing location, partnership models, and inventory practices.

Ultimately, the path forward requires pragmatic collaboration across industry, government, and academic sectors to balance innovation with access. By adopting the strategic actions outlined in this analysis, organizations can convert scientific potential into durable public health impact while managing financial and operational risk.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaccine Adjuvants Market, by Delivery Route

  • 8.1. Intramuscular
  • 8.2. Intranasal
  • 8.3. Oral
  • 8.4. Subcutaneous

9. Vaccine Adjuvants Market, by Formulation

  • 9.1. Emulsions
  • 9.2. ISCOMs
  • 9.3. Liposomes
  • 9.4. Particulates
  • 9.5. Saponin Complexes

10. Vaccine Adjuvants Market, by Vaccine Category

  • 10.1. Bacterial Vaccines
  • 10.2. DNA Vaccines
  • 10.3. mRNA Vaccines
  • 10.4. Recombinant Vaccines
  • 10.5. Viral Vaccines

11. Vaccine Adjuvants Market, by End User

  • 11.1. Clinics
    • 11.1.1. Outpatient Clinics
    • 11.1.2. Specialty Clinics
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Research Institutes
    • 11.3.1. Government Institutes
    • 11.3.2. Private Laboratories

12. Vaccine Adjuvants Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Vaccine Adjuvants Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Vaccine Adjuvants Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Vaccine Adjuvants Market

16. China Vaccine Adjuvants Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agenus, Inc.
  • 17.6. Aphios Corporation
  • 17.7. Bioveta, A.S.
  • 17.8. Croda International PLC
  • 17.9. CSL Limited
  • 17.10. Dynavax Technologies Corporation
  • 17.11. GlaxoSmithKline PLC
  • 17.12. Hayashibara Co. Ltd.
  • 17.13. InvivoGen
  • 17.14. Merck KGaA
  • 17.15. MVP Laboratories, Inc.
  • 17.16. Novavax, Inc.
  • 17.17. OZ Biosciences
  • 17.18. Pacific GeneTech Limited
  • 17.19. Seppic S.A.
  • 17.20. SHIONOGI & Co., Ltd.
  • 17.21. SPI Pharma, Inc.
  • 17.22. Takeda Pharmaceutical Company Limited
  • 17.23. Thermo Fisher Scientific Inc.
  • 17.24. Vaxine Pty Ltd.
  • 17.25. Zoetis Services LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VACCINE ADJUVANTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VACCINE ADJUVANTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA VACCINE ADJUVANTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY EMULSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY EMULSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY EMULSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ISCOMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ISCOMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ISCOMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SAPONIN COMPLEXES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SAPONIN COMPLEXES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SAPONIN COMPLEXES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY BACTERIAL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY BACTERIAL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY BACTERIAL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RECOMBINANT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RECOMBINANT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VIRAL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VIRAL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VIRAL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY GOVERNMENT INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY GOVERNMENT INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY GOVERNMENT INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRIVATE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRIVATE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRIVATE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 152. GCC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 155. GCC VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. GCC VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 176. G7 VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 179. G7 VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. G7 VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 184. NATO VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. NATO VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. NATO VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. NATO VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA VACCINE ADJUVANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA VACCINE ADJUVANTS MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA VACCINE ADJUVANTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA VACCINE ADJUVANTS MARKET SIZE, BY VACCINE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA VACCINE ADJUVANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA VACCINE ADJUVANTS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA VACCINE ADJUVANTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA VACCINE ADJUVANTS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)